Know Cancer

or
forgot password

Intravitreal Injections of Melphalan for Retinoblastoma


N/A
N/A
20 Years
Not Enrolling
Both
Retinoblastoma

Thank you

Trial Information

Intravitreal Injections of Melphalan for Retinoblastoma


Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or
with vitreal seeding of the disease.


Inclusion Criteria:



- Retinoblastoma that has not responded to chemotherapy

- Retinoblastoma that has vitreal seeding

Exclusion Criteria:

- previous failure of IVit Melphalan

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

treatment response

Outcome Description:

short term response to treatment and long term complications

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Shahar Frenkel, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hadassah Medical Organization

Authority:

Israel: Ministry of Health

Study ID:

RB-001-HMO-CTIL

NCT ID:

NCT01558960

Start Date:

March 2012

Completion Date:

March 2013

Related Keywords:

  • Retinoblastoma
  • Retinoblastoma
  • Retinoblastoma

Name

Location